IRIS
Caffo, Orazio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.713
AS - Asia 1.173
EU - Europa 1.076
Continente sconosciuto - Info sul continente non disponibili 291
SA - Sud America 159
AF - Africa 31
OC - Oceania 3
Totale 4.446
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.649
IT - Italia 531
SG - Singapore 424
CN - Cina 202
VN - Vietnam 188
DE - Germania 132
BR - Brasile 117
FI - Finlandia 95
RU - Federazione Russa 95
BD - Bangladesh 88
HK - Hong Kong 81
KR - Corea 64
FR - Francia 42
GB - Regno Unito 41
CA - Canada 33
IN - India 29
ID - Indonesia 23
LV - Lettonia 23
NL - Olanda 23
SE - Svezia 20
IQ - Iraq 14
MX - Messico 14
AR - Argentina 13
PL - Polonia 13
AT - Austria 12
IE - Irlanda 12
SA - Arabia Saudita 10
UA - Ucraina 10
ZA - Sudafrica 10
JP - Giappone 9
TR - Turchia 8
EC - Ecuador 7
VE - Venezuela 6
CZ - Repubblica Ceca 5
JO - Giordania 5
PK - Pakistan 5
CO - Colombia 4
ES - Italia 4
NP - Nepal 4
PH - Filippine 4
PR - Porto Rico 4
UY - Uruguay 4
CL - Cile 3
EG - Egitto 3
GT - Guatemala 3
KE - Kenya 3
MA - Marocco 3
MY - Malesia 3
PE - Perù 3
AL - Albania 2
BG - Bulgaria 2
CR - Costa Rica 2
DZ - Algeria 2
HN - Honduras 2
HU - Ungheria 2
LT - Lituania 2
MK - Macedonia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LS - Lesotho 1
LU - Lussemburgo 1
LY - Libia 1
MT - Malta 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
VC - Saint Vincent e Grenadine 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 4.155
Salva come PNG Salva come JPEG
Città #
Singapore 301
Ashburn 192
San Jose 190
Trento 173
Council Bluffs 157
Munich 103
Columbus 96
Santa Clara 89
Helsinki 74
Hong Kong 74
Milan 67
Dallas 64
Los Angeles 63
Seoul 62
Ho Chi Minh City 55
New York 47
Fairfield 41
Hanoi 37
Rome 37
Chandler 36
Chicago 35
Moscow 31
Beijing 28
Houston 27
Riga 23
Lauterbourg 21
The Dalles 21
Verona 19
Da Nang 17
Jacksonville 16
Orem 16
Wilmington 16
Ogden 15
Seattle 15
Buffalo 13
Princeton 13
Atlanta 12
Jakarta 12
Hefei 11
Nuremberg 11
St Louis 11
São Paulo 11
Toronto 11
Boardman 10
Cambridge 10
Shenzhen 10
Warsaw 10
Woodbridge 10
Chennai 9
Mattarello 9
Miano 9
Salt Lake City 9
San Mateo 9
Ann Arbor 8
London 8
North Bergen 8
Tokyo 8
Dublin 7
Frankfurt am Main 7
Lappeenranta 7
Vienna 7
Baghdad 6
Cincinnati 6
Denver 6
Figino 6
Florence 6
Jyväskylä 6
Modena 6
Paris 6
Redondo Beach 6
Tampa 6
Vicenza 6
Waterbury 6
Amman 5
Bologna 5
Boston 5
Curitiba 5
Daiano 5
Falkenstein 5
Haiphong 5
Istanbul 5
Johannesburg 5
Manchester 5
Mexico City 5
Montreal 5
Phoenix 5
Shanghai 5
Bari 4
Can Tho 4
Como 4
Dammam 4
Detroit 4
Genoa 4
Hải Dương 4
Jersey City 4
Miami 4
Philadelphia 4
Queens 4
San Francisco 4
Venice 4
Totale 2.712
Salva come PNG Salva come JPEG
Nome #
A model-based framework to identify optimal administration protocols for immunotherapies in castration-resistance prostate cancer 258
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 172
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer 172
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? 163
TRPM8 levels determine tumor vulnerability to channel agonists. 146
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment 140
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation 137
Integrating extracellular vesicle and circulating cell-free DNA analysis on a single plasma aliquot improves the detection of HER2 positivity in breast cancer patients 137
Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? 135
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations 133
Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma 122
1730P Electronic medical record (EMR)-assisted phone follow-up (PFU) for breast cancer survivors (CS) during COVID-19 pandemic: An Italian single institution experience 114
Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience 112
Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti PD1/PDL1 therapy 108
Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study 92
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis 90
Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature 72
Tissue microarrays in oncology. 70
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer 67
Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma 63
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 58
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives 57
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis 52
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials 52
Prostate Cancer Diagnosis and Treatment in Elderly Patients: A Cross-Sectional Survey Exploring Practice Patterns and Preferences of Uro-Oncologists in Northeast Italy 47
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study 43
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study 42
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study 41
Radioligand Therapies (RLTs) and Healthcare System Readiness: From the Experience in GEP-NET, a Retrospective Analysis on DRG and Mobility to Improve the Accessibility to the Future RLT in Italy 38
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide 36
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 36
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis 36
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 35
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 35
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? 34
Association of G8 screening tool with prognosis and survival in patients with non-small cell lung cancer: A retrospective analysis from a single institution 33
Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases 32
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC 31
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma 30
Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO) 29
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 29
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study 28
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study 28
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 28
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line 28
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study 27
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 27
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 27
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) 27
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab 26
Darolutamide Maintenance in Patients With Metastatic Castration- Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 26
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 26
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 26
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study 25
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study) 25
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 25
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology 24
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 24
Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU) 24
The Expanding Role of Next-generation Imaging in Prostate Cancer Management: A Cross-sectional Survey Exploring the Clinical Practice of Uro-oncologists in North-Eastern Italy; On Behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 23
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study 23
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 23
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 22
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 21
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021 20
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 20
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 20
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 20
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer 19
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 18
A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer 18
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone 17
Prostate cancer: Screening and early detection 16
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network 16
Prognostic Value of p21WAF1 and p53 Expression in Breast Carcinoma: An Immunohistochemical Study in 261 Patients with Long-Term Follow-Up 16
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials 13
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. 13
Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology 13
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 13
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. 13
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. 12
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer 12
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer 12
Use of the ONCO-TreC electronic diary compared with a standard paper diary to improve adherence to oral cancer therapy in patients with solid and haematological tumours: protocol for a randomised controlled trial 12
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. 11
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study 11
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review 10
Learning from organisational changes in the management of breast cancer patients during the COVID-19 pandemic: Preparing for a second wave at a breast unit in northern Italy 10
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis. 10
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial 9
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 9
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. 9
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? 9
Pain and quality of life after surgery for breast cancer 8
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients 8
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM) 8
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial 8
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 7
Docetaxel rechallenge in patients with castration-resistant prostate cancer - A review 7
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM) 7
Totale 4.366
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.900
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.900
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202299 0 1 0 12 12 0 13 25 6 2 9 19
2022/202380 10 13 0 11 5 11 1 3 7 7 8 4
2023/202482 4 2 4 2 3 8 4 10 5 13 9 18
2024/2025814 13 11 43 108 49 88 86 58 94 104 41 119
2025/20262.705 104 47 141 204 137 87 237 74 724 515 142 293
2026/2027541 212 329 0 0 0 0 0 0 0 0 0 0
Totale 4.446